Hematology and Oncology Practice Risk Guide

A molecular result can return after a patient has left. An oral therapy can be delayed or missed. A febrile patient can call after an infusion when the usual clinician is unavailable. A treatment plan is not a prescription. It is a living loop: diagnosis and molecular evidence, regimen decision, preparation or dispensing, toxicity and lab or imaging review, then the next-cycle decision or handoff.

The practice should be able to identify a current clinical owner and backup at every turn in that loop.

Make results clinically usable

For biopsy, pathology, molecular testing, imaging, and outside consultations, distinguish collection-only work, an external reference laboratory, in-house testing, and a research assay. Then identify who reconciles the result, interprets it in the patient's context, discusses it with the patient, changes treatment or surveillance, and follows an addendum or discordant finding.

CLIA applies to patient-specific results used for diagnosis, prevention, treatment, or individual health assessment, unless an exception applies. The research exception is narrow: it covers testing that does not report patient-specific results for those clinical purposes. A California site that performs clinical testing generally needs the applicable California laboratory authority and federal CLIA certificate. Do not confuse a clinic that collects a specimen with a laboratory that performs the test.

For a laboratory that is subject to CLIA systems requirements, specimen identification, handling, processing, reporting, and referral procedures need to be controlled. For the oncology practice, turn that into a traceability map rather than an invented legal chain-of-custody rule for every handoff.

Give each delivery pathway its own care map

The same drug creates different work when it is infused, injected, dispensed orally, or studied under a protocol.

Clinic-administered treatment: map regimen decision, order verification, preparation source, patient identification, access and administration, infusion-reaction response, emergency and transfer route, toxicity communication, and next-cycle decision.
Oral therapy: map initial assessment, interaction review, patient education, dispensing and access, refill and adherence contact, lab or imaging review, urgent symptom route, and treatment hold or change authority.
Compounded product, if used: identify the formulation, source, pharmacy pathway, and applicable policy and quality questions. Compounded drugs are not FDA approved; that fact does not by itself decide safety, appropriateness, or coverage.

The practice needs a risk-appropriate way to reach a clinician for fever, bleeding, new neurologic or respiratory symptoms, pain or refill questions, missed monitoring, and missed appointments. A generic emergency instruction does not tell staff or patients who can assess the situation, see the current regimen, or close the task.

Treat infusion safety as a whole-setting decision

Map the professional group, infusion entity, pharmacy, nurses, pumps and chairs, hazardous-drug processes, emergency supplies, transfer route, record, and after-hours coverage. Identify who can delay, hold, or change a regimen, and how that decision reaches the patient, pharmacy, and infusion staff.

Medication administration, premises, drug stock, equipment, data, and staffing can involve different entities and contracts. Do not assume a policy named for one risk automatically responds to another. Read the actual insuring agreement, definitions, exclusions, endorsements, and contracts.

Keep the specialty interfaces visible

Radiation oncology, surgery, transplant or cellular therapy, pathology, genetics, palliative care, primary care, and hospital services are not footnotes to medical oncology. For every active interface, identify the referral or order, report recipient, shared record route, urgent toxicity or complication path, and the clinician who continues to coordinate the oncology plan.

Radiation use can involve CDPH radioactive-material licensing or registration and facility-specific rules, depending on the actual modality and site. A referral does not make the medical-oncology practice responsible for every radiation operation, and a radiation relationship does not establish one shared insurance policy. The same principle applies to hospitals, laboratories, and pharmacies.

Give research its own regulatory decision tree

Research is not one blanket paperwork package. Common Rule coverage applies only to the research it governs, while FDA-regulated drug or device studies have separate investigator, consent, IRB, record, investigational-product, and reporting duties. California's medical-experiment statutes, protocol terms, and site rules create additional fact-specific questions.

Before a study begins, map the sponsor, site, PI, protocol, participant communication, results that may enter clinical care, specimen and data flow, treatment of incidental or actionable findings, end-of-study care transition, and contract or insurance terms. A delegation record assigns tasks; it does not by itself transfer the investigator's regulatory responsibility. A study label does not make a patient-specific clinical result nonclinical.

Preserve medical judgment across the entity map

Map the professional practice, infusion entity, laboratory, pharmacy relationship, research entity, radiation interface, MSO, and property entity. California's corporate-practice rules preserve professional medical judgment over regimen selection, toxicity response, referrals, records, clinical competence, and medical equipment and supplies. A business structure cannot convert those into administrative decisions.

For clinicians, pharmacists, nurses, advanced clinicians, coordinators, temporary staff, and covering physicians, map actual tasks, competence, record access, escalation, and effective dates. Do not use a title or a certificate as a substitute for the care model.

Use insurance as the final document check

After the treatment map is concrete, compare the people, entities, sites, infusion and oral therapy workflows, laboratory and pharmacy relationships, research work, radiation interfaces, and historical services with the application, declarations, definitions, endorsements, exclusions, and contracts. Ask which person or entity qualifies as an insured, whether limits and defense costs are shared, and how claims-made reporting, prior acts, or extended reporting work after a transition.

If Schedule II through IV controlled medications are part of the oncology program, California's CURES consultation rule generally requires review of the patient's prior 12-month history before the first intent to prescribe, order, administer, or furnish and at least every six months while treatment continues, subject to material statutory exceptions. Use a report obtained no earlier than 24 hours or the prior business day. This is a narrow controlled-substance branch, not a substitute for the broader medication and toxicity plan.

Test the weekend: a molecular addendum changes the regimen, an infusion reaction occurs, an oral refill is missed, a febrile patient calls, and a study site closes. The practice should be able to name the clinical owner, backup, record route, next decision, and relevant policy or contract contact.

A regimen is a living loop, not an order set.